The expanding field of immunotherapy relies heavily on recombinant mediator technology, and a thorough understanding of individual profiles is paramount for fine-tuning experimental design and therapeutic efficacy. Specifically, examining the attributes of recombinant IL-1A, IL-1B, IL-2, and IL-3 reveals important differences in their structure, bi